IO BIOTECH INC. news, videos and press releases
For more news please use our advanced search feature.
IO BIOTECH INC. - More news...
IO BIOTECH INC. - More news...
- IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
- IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
- IO Biotech Announces Participation in Upcoming Investor Conferences
- IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights
- IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
- IO Biotech to Present at Jefferies Global Healthcare Conference
- IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
- IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
- IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
- IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
- IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
- IO Biotech to Present at 44th Annual Cowen Health Care Conference
- IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
- IO Biotech Announces 2023 Third Quarter Results
- IO Biotech Appoints Helen Collins, MD, to its Board of Directors
- IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
- IO Biotech Announces Participation in Upcoming Investor Conferences
- IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress
- IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
- IO Biotech Announces Participation in Upcoming Investor Conferences
- IO Biotech Announces 2023 Second Quarter Results
- IO Biotech Appoints Heidi Hunter to its Board of Directors
- IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
- IO Biotech, Inc. Announces $75 Million Private Placement Financing
- IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center
- IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer
